The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

In patients with hypercortisolism and inadequately controlled type 2 diabetes, mifepristone lowered HbA1c levels by about 1.5 ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound ...

Find the latest Metsera, Inc. (MTSR) stock quote, history, news and other vital information to help you with your stock trading and investing.

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial. Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...